Table 1.
Descriptive characteristics of the study group.
| Number (%) | Median (IQR) a | |
|---|---|---|
| Patients | 62 (100%) | |
| Male | 28 (45.2%) | |
| Female | 34 (54.8%) | |
| Age at diagnosis (years) | 4.13 (3.03–6.45) | |
| Age at study (years) | 12.39 (8.17–16.08) | |
| Follow-up after treatment (years) | 7.05 (2.24–9.07) | |
| Overweight | 18 (29%) | |
| Obese | 10 (16%) | |
| Glucocorticoids: | ||
| Cumulative corticosteroid dose (mg/m2) c | 62 (100%) | 3087 (3087–3087) b |
| Prednisone (cumulative dose in mg/m2) | 62 (100%) | 1680 (1680–1680) b |
| Dexamethasone (cumulative dose in mg/m2) | 62 (100%) | 210 (210–210) b |
| Radiotherapy | 9 (14.5%) | |
| Cranial radiotherapy (CRT) (cumulative dose in Grey) | 8 (12.9%) | 12 (12–12) b |
| Total body irradiation (TBI) | 2 (3.23%) | 12 (12–12) b |
| No | 53 (85.5%) | |
| HSCT | 6 (9.7%) | |
| Metabolic derangements | ||
| 1 Metabolic risk factor | 23 (37.1%) | |
| 2 Metabolic risk factors | 5 (8.1%) | |
| 3 Metabolic risk factors | 4 (6.5%) | |
| 4 Metabolic risk factors | 1 (1.6%) |
a Interquartile range (IQR). b Most patients received the same dosage of anticancer agents according to the treatment protocol; therefore, the first and third quartiles did not differ from the median. c Calculated as prednisone equivalents.